| Old Articles: <Older 8571-8580 Newer> |
|---|
 |
Chemistry World
April 9, 2013
Emma Stoye |
Drug restrictions delay magic mushroom trial The first clinical trial to explore the antidepressant effects of psilocybin, the hallucinogenic component of magic mushrooms, has been delayed by EU and UK drug regulations.   |
Chemistry World
April 8, 2013
Sarah Houlton |
India rejects Novartis patent appeal India's Supreme Court has denied Novartis' appeal against the decision to refuse patent protection for its anticancer drug Glivec (imatinib mesylate). |
Chemistry World
April 8, 2013
Philip Robinson |
The truth about snake oil? US scientists have carried out the first analyses of old 'patent medicines' - medicinal preparations from the turn of the last century - to identify the chemical constituents of the medications and perhaps determine if there was any truth in the wild health claims they made. |
Chemistry World
April 5, 2013
Phillip Broadwith |
Roche to release Tamiflu trial data Swiss pharma company Roche has finally agreed to give independent researchers access to data on all 74 clinical trials it ran on the antiviral influenza drug Tamiflu (oseltamivir). |
Chemistry World
April 4, 2013
Phillip Broadwith |
Regeneron expands, creating 400 new jobs US biotech Regeneron has announced that it will expand its corporate headquarters and laboratories in Tarrytown. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
Chemistry World
April 2, 2013
Kerek Lowe |
From lab to leader Here's a topic that always gets people arguing: how much of a scientist should the chief executive of a biopharma company be? |
Chemistry World
April 2, 2013
Bibiana Campos Seijo |
More job cuts... The news came in that AstraZeneca is to invest 330 million pounds in a new strategic R&D center and global headquarters in Cambridge, UK. Unfortunately, there is also a negative angle to this story. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
Pharmaceutical Executive
March 1, 2013 |
China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China. |
| <Older 8571-8580 Newer> Return to current articles. |
